Navigation Links
Ikaria(R) Receives FDA Orphan Drug Designation for Inhaled Carbon Monoxide for Delayed Graft Function in Solid Organ Transplants
Date:8/10/2008

CLINTON, N.J., July 28 /PRNewswire/ -- Ikaria Holdings, Inc., a fully integrated critical care biotherapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for inhaled carbon monoxide for use in the reduction of the incidence and severity of delayed graft function (DGF) in patients undergoing solid organ transplantation.

Ralf Rosskamp, M.D., Executive Vice President of Research and Development for Ikaria, commented, "The designation of orphan drug status is a significant step that will greatly facilitate the development of inhaled carbon monoxide as a potential treatment for DGF in solid organ transplants. Pre-clinical data has demonstrated that the compound may possess anti-inflammatory, cytoprotective and anti-apoptotic properties that could potentially improve ischemic-reperfusion mediated malfunction in transplanted organs and allow for an important advance in solid organ transplantation. We look forward to advancing our research of inhaled carbon monoxide as part of our overall goal of delivering new therapies for the underserved critical care market."

Ikaria is currently conducting a single-blind, placebo controlled, dose-escalating Phase 2 study of inhaled carbon monoxide in patients receiving renal transplants. The primary endpoint of the study is to evaluate the safety and tolerability of increasing carbon monoxide dose levels when administered as an inhaled gas to kidney transplant patients over the course of one hour in an acute hospital setting. The study was initiated in August 2007 and is currently enrolling patients.

Delayed graft function following kidney transplantation represents an unmet medical need with considerable health burdens. DGF occurs when the kidney does not function sufficiently after transplantation, often requiring dialysis to support the patient. The underlying cause of DGF is ischemia-reperfusion injury, which occurs when blood flow is retu
'/>"/>

SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Ikaria(R) Receives FDA Orphan Drug Designation for Inhaled Carbon Monoxide for Delayed Graft Function in Solid Organ Transplants
2. Artificial Gravity receives 2008 Life Science Book Award
3. Colorado Sen. Ken Salazar receives Soil Stewardship Award
4. Childrens Memorial Hospital of Chicago receives a grant from BioMarin to support adult PKU outreach
5. Engineer receives $1.5M grant for nanoparticle cancer research
6. UC Riverside bioengineer receives high honor from chemical engineers
7. Pitt receives $2.5 million to simulate and analyze brain, immune system activity
8. NJIT biomedical engineer receives NSF Career Development Award
9. Monash researcher receives prestigious Commonwealth Health Ministers award
10. Spradling receives Gruber Foundation Genetics Prize for new genetic techniques
11. UNH receives $380,000 grant to study organic dairy as closed ecosystem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Europe,s most prestigious innovation prize ... present a video retrospective of the most exciting and innovative nominations  ... and Sophie Wilson   A different theme ... Starting on 22 January 2015 on   http://www.epo.org/european-inventor   ...
(Date:12/22/2014)...  NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" ... growing mobile commerce market, announces it has retained famous pickpocket, ... 2015 International CES debut of the Wocket™ biometric smart wallet.  ... the NXT-ID booth January 6th and 7 th , 2015, ...
(Date:12/19/2014)... Inc., the leading personal genetics company, today announced the publication ... of individuals from across the United States ... hundred years ago, the United States ... continents. This study illuminates how American history and the ongoing ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... , From neurosurgery to bar code readers, lasers have been ... introduced in the late 1950,s. Now, with the work being ... developed a way to use lasers to study the splicing ... to sustain advanced organisms, including human life. This process of ...
... study led by a University of Florida researcher uses tracking ... some of the fish swim directly to targeted locations. ... orient at large distances, with tiger sharks swimming in direct ... areas about 30 miles away, said lead author Yannis Papastamatiou, ...
... been selected as one of seven recipients to share ... to promote preventive care and reduce health care disparities ... its Centering Pregnancy program to address perinatal health care ... bring pregnant women with similar backgrounds together for group ...
Cached Biology News:Brandeis researchers use lasers, custom microscope to show gene splicing process in real time 2Brandeis researchers use lasers, custom microscope to show gene splicing process in real time 3New UF study shows some sharks follow 'mental map' to navigate seas 2New UF study shows some sharks follow 'mental map' to navigate seas 3Boston Medical Center to receive $245,000 grant from Attorney General Martha Coakley 2
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited to ... on probiotics in San Diego, CA. , The Scripps ... health care professionals. This year’s pre-conference seminar was held on ... Dr. Leyer spoke about the emerging topics and science in ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015 ... Research abre hoy su llamada a nominaciones para 2015. ... científica ha hecho, o tiene el potencial para hacer, ... Las nominaciones se aceptarán hasta el 15 de marzo ...
(Date:1/22/2015)... , Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... focused on advanced wound care, announces that AMNIOEXCEL® ... have been added to the Premier, Inc. Regenerative ... opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product lines, ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... -- Huifeng Bio-,Pharmaceutical Technology, Inc (OTC Bulletin Board: ... and pharmaceutical raw materials,for use in pharmaceutical, nutraceutical ... and earnings for the three and six month ... half of 2008, sales of our products increased,substantially. ...
... 14 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... development and commercialization of novel drugs in the,therapeutic ... its financial results for the second quarter ended ... The net loss for the three months ...
... Aug. 14 /PRNewswire-FirstCall/ - Ondine Biopharma,Corporation (the ... a medical,technology company developing photodisinfection based products, ... quarter ended June 30, 2008., "During ... and clinical,progress with our photodisinfection technology and ...
Cached Biology Technology:Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008 2Advanced Life Sciences Announces Second Quarter 2008 Financial Results 2Advanced Life Sciences Announces Second Quarter 2008 Financial Results 3Advanced Life Sciences Announces Second Quarter 2008 Financial Results 4Advanced Life Sciences Announces Second Quarter 2008 Financial Results 5Advanced Life Sciences Announces Second Quarter 2008 Financial Results 6Advanced Life Sciences Announces Second Quarter 2008 Financial Results 7Advanced Life Sciences Announces Second Quarter 2008 Financial Results 8Advanced Life Sciences Announces Second Quarter 2008 Financial Results 9Advanced Life Sciences Announces Second Quarter 2008 Financial Results 10Ondine Biopharma Announces Second Quarter 2008 Financial Results 2Ondine Biopharma Announces Second Quarter 2008 Financial Results 3Ondine Biopharma Announces Second Quarter 2008 Financial Results 4Ondine Biopharma Announces Second Quarter 2008 Financial Results 5Ondine Biopharma Announces Second Quarter 2008 Financial Results 6Ondine Biopharma Announces Second Quarter 2008 Financial Results 7Ondine Biopharma Announces Second Quarter 2008 Financial Results 8Ondine Biopharma Announces Second Quarter 2008 Financial Results 9Ondine Biopharma Announces Second Quarter 2008 Financial Results 10Ondine Biopharma Announces Second Quarter 2008 Financial Results 11Ondine Biopharma Announces Second Quarter 2008 Financial Results 12Ondine Biopharma Announces Second Quarter 2008 Financial Results 13Ondine Biopharma Announces Second Quarter 2008 Financial Results 14Ondine Biopharma Announces Second Quarter 2008 Financial Results 15Ondine Biopharma Announces Second Quarter 2008 Financial Results 16Ondine Biopharma Announces Second Quarter 2008 Financial Results 17
DNA sequencing - plasmids or PCR fragments, 3-7 working days service....
Polyclonal Antibody to Golgin-67...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Peptide-affinity Purified Polyclonal Antibody to MTR...
Biology Products: